Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01430494 · ClinicalTrials.gov registry record

Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease

A clinical trial of Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
3,409
Enrollment target
20
Study locations

NCT01430494 is a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD) that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 3,409 participants, above the 110-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (2999% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01430494, a study of Autosomal Dominant Polycystic Kidney Disease (ADPKD), has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
3,409 participants
Enrollment target
20
Study locations

Study Summary

To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population at increased risk for disease progression. The economic and quality life impact of ADPKD will be assessed. Subjects who terminated participation early from clinical trials with tolvaptan may also be followed.

Conditions Studied

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Locations (20)

California

  • Otsuka Investigational Site - Azusa
  • Otsuka Investigational Site - Bakersfield
  • Otsuka Investigational Site - Los Angeles
  • Otsuka Investigational Site - Los Angeles
  • Otsuka Investigational Site - Ontario
  • Otsuka Investigational Site - San Diego

Florida

  • Otsuka Investigational Site - Coral Gables
  • Otsuka Investigational Site - Hudson
  • Otsuka Investigational Site - Jacksonville
  • Otsuka Investigational Site - Melbourne
  • Otsuka Investigational Site - Port Charlotte
  • Otsuka Investigational Site - Tampa

Arizona

  • Otsuka Investigational Site 1 - Peoria
  • Otsuka Investigational Site 2 - Peoria
  • Otsuka Investigational Site - Tempe

Colorado

  • Otsuka Investigational Site - Arvada
  • Otsuka Investigational Site - Aurora
  • Otsuka Investigational Site - Denver

Connecticut

  • Otsuka Investigational Site - New Haven

District of Columbia

  • Otsuka Investigational Site - Washington D.C.

Trial Details

FieldValue
Enrollment Target 3,409 participants
Start Date 2011-06
Est. Completion 2014-10

Sponsor

Otsuka Pharmaceutical Development & Commercialization

221 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01430494

The ClinicalTrials.gov registry entry for NCT01430494 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,409 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 110-participant average among 5 other Autosomal Dominant Polycystic Kidney Disease (ADPKD) trials with a reported enrollment target (2999% higher). The listed sponsor is Otsuka Pharmaceutical Development & Commercialization, which has 221 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Autosomal Dominant Polycystic Kidney Disease (ADPKD) appearing as the primary indexed condition, and to 0 interventions.

NCT01430494 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01430494 about?

NCT01430494 is a clinical study titled "Observational Study in Patients With Autosomal Dominant Polycystic Kidney Disease". To collect characteristics of patients with ADPKD across a broad population, over time to better understand disease progression (signs, symptoms and outcomes). Association with total kidney volume changes and other measures of disease progression will be determined in order to identify a population ...

What is the current status of trial NCT01430494?

This trial is currently completed. The enrollment target is 3,409 participants. The study started on 2011-06. Estimated completion is 2014-10.

What conditions does trial NCT01430494 study?

This clinical trial studies the following conditions: Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Who is sponsoring clinical trial NCT01430494?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01430494 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.